REGENEREX PHARMA, INC. Quarterly Debt-to-equity in % from Q4 2019 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Regenerex Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q4 2019 to Q4 2024.
  • Regenerex Pharma, Inc. Debt-to-equity for the quarter ending December 31, 2024 was -115 %, a 10.7% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 -115 +13.9 +10.7% Dec 31, 2024
Q3 2024 -118 +11.2 +8.72% Sep 30, 2024
Q2 2024 -121 +4.05 +3.25% Jun 30, 2024
Q1 2024 -128 -27.5 -27.3% Mar 31, 2024
Q4 2023 -129 -28.1 -27.7% Dec 31, 2023
Q3 2023 -129 -27.6 -27.3% Sep 30, 2023
Q2 2023 -125 -23.4 -23.1% Jun 30, 2023
Q1 2023 -101 +0.51 +0.5% Mar 31, 2023
Q4 2022 -101 +0.18 +0.18% Dec 31, 2022
Q3 2022 -101 +7.9 +7.24% Sep 30, 2022
Q2 2022 -101 +17.8 +14.9% Jun 30, 2022
Q1 2022 -101 +30.9 +23.4% Mar 31, 2022
Q4 2021 -101 +48.8 +32.5% Dec 31, 2021
Q3 2021 -109 +44 +28.7% Sep 30, 2021
Q2 2021 -119 +36.6 +23.5% Jun 30, 2021
Q1 2021 -132 +19.9 +13.1% Mar 31, 2021
Q4 2020 -150 -3.74 -2.56% Dec 31, 2020
Q3 2020 -153 Sep 30, 2020
Q2 2020 -156 Jun 30, 2020
Q1 2020 -152 Mar 31, 2020
Q4 2019 -146 Dec 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.